Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01282684 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PLX5622 in Healthy Adult Volunteers
A Phase 1 study, sponsored by Plexxikon.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT01282684 is a Phase 1 study that has completed, run by Plexxikon. The registered enrollment target is 32 participants.
The verdict
NCT01282684, a Phase 1 study, has completed, sponsored by Plexxikon.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of this study is to study the safety and tolerability of a single dose of PLX5622 in healthy, adult human volunteers. This will be the first time PLX5622 has been taken by humans.
Interventions
- DRUG Placebo
- DRUG PLX5622
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2011-01 |
| Est. Completion | 2011-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01282684
The ClinicalTrials.gov registry entry for NCT01282684 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Plexxikon, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01282684 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01282684 about?
NCT01282684 is a clinical study titled "Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PLX5622 in Healthy Adult Volunteers". The purpose of this study is to study the safety and tolerability of a single dose of PLX5622 in healthy, adult human volunteers. This will be the first time PLX5622 has been taken by humans.
What is the current status of trial NCT01282684?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2011-01. Estimated completion is 2011-04.
What interventions are being tested in trial NCT01282684?
The interventions under investigation include: Placebo (DRUG), PLX5622 (DRUG).
Who is sponsoring clinical trial NCT01282684?
This trial is sponsored by Plexxikon, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.